Shout Out to
@AaronBosterMD
! Dr. Boster is a superstar in the MS community and known for being exceptionally patient-oriented and skilled at simplifying complex MS topics. We're thrilled to profile Dr. Boster and his amazing work on our Twitter today.
Nearly half of 757 relapsing MS patients given Ocrevus early in disease course had no evidence of disease activity 9 years out, study finds.
#aan2023
#news
A possibly groudbreaking treatment that restores myelin has been cleared by the FDA for a Phase 1b/2a trial. Most approved MS medicines focus on immune modulation rather than remyelination, so this treatment would be the first of its kind.
#msnews
#ms
The second SPMS patient given experimental foralumab nasal spray showed significant functional improvements after six months and is now able to walk 100 meters without a cane or need for rest.
#multiplesclerosis
#msnews
#msawareness
#msresearch
Repairing lost myelin is seen by many as a “holy grail” quest for disease treatment. Researchers are now closer with a new clinical trial that is testing whether an antihistamine in combination with a diabetes medication might promote remyelination.
#MSnews
Treatment with polysialic acid increased myelin repair in a cell model of MS by altering the activity of brain immune cells called microglia, a study finds.
#news
Experimental therapy NVG-291 has been shown to be well tolerated in an ongoing study. It is expected to help promote nervous system repair, including restoration of the myelin sheath that’s damaged in MS.
#multiplesclerosis
#msnews
#msawareness
#msresearch
In MS, T-cells drive the body’s mistaken immune system attack on healthy parts of the nervous system. Researchers have now identified four new brain proteins targeted by these cells, which could result in new, more specific treatments.
#multiplesclerosis
A new study reveals that in MS, damage to the myelin sheath causes increased levels of VLCFAs, which are converted into an inflammation-driving molecule called S1P, presenting potential treatment options.
#multiplesclerosis
#msnews
#msawareness
#msresearch
Stem cell therapy was better than Gilenya and Tysabri, but not Ocrevus, at reducing disability for people with aggressive RRMS, an analysis suggests.
#news
The Octopus clinical trial is testing multiple therapies at the same time to accelerate the development of treatments for progressive MS. The trial currently is recruiting participants in the U.K.
#multiplesclerosis
#msnews
#msresearch
Protein Mfsd2a deficiency was found to play a key role in myelin sheath production. Researchers now plan to conduct studies to see if dietary omega-3 can help remyelination.
#multiplesclerosis
#msnews
#msawareness
#msresearch
A new treatment approach could prevent abnormal immune cells from reaching the brain and spinal cord and causing nerve cell damage — and it might do so without the side effects of current MS therapies.
#multiplesclerosis
#msnews
#msawareness
#msresearch
EBViously announced that it has developed a candidate vaccine against the Epstein-Barr virus. The company plans to move it to clinical trials in 2024 with the first test aimed at preventing mononucleosis.
#multiplesclerosis
#msnews
#msresearch
Welcome to Day 1 of the ACTRIMS Forum 2023! The MS News Today team is on-site and will be reporting live throughout the conference. We’ve got a lot of great stuff coming up. Stay tuned!
#actrims2023
A new study has found that drinking black and green tea, coffee, and nonalcoholic beer may reduce the risk of developing MS, while carbonated drinks, milk, and fruit juices may increase it.
#multiplesclerosis
#msnews
#msawareness
#msresearch
With MS, diet is important. Saturated fat intake has been linked to a risk of MS relapses and disease progression. We explain this further in our new resource on diet and MS.
#multiplesclerosis
#msnews
#msawareness
#msresearch
Disability progression in people with MS reduces their life quality and ability to work, and increases healthcare costs, a study in Germany finds.
#news
A candidate vaccine against the Epstein-Barr virus is set for clinical trials in 2024, with the first test targeting mononucleosis prevention.
#multiplesclerosis
#msnews
#msresearch